DCSIMG

© 2010, Bayer Schering Pharma AG
This website is intended to provide information to an international audience outside the USA and UK.
Last updated on 9th March 2010

Benefit Calculator

Determine the number of VTE events you could potentially prevent in a given year when using Xarelto® instead of enoxaparin, taking the RECORD1 and RECORD3 clinical trial data as reference for the calculation.

TOTAL KNEE REPLACEMENT
TOTAL HIP REPLACEMENT

Procedures per year

Elective knee replacement surgeries performed per year

Number of events

Symptomatic VTE avoided
Major VTE avoided
Total VTE avoided
Additional bleeding *

* Bleeding was similar in both treatment groups; major and non-major bleeding combined; see publication for detailed definition 4

RECORD3 trial compared 10 mg rivaroxaban with 40 mg enoxaparin for 2 weeks in 2531 patients undergoing elective knee replacement surgery. Calculations based on RECORD3 data published in the New England Journal of Medicine 4; numbers rounded to full digits.

Note, the experience reported from a controlled clinical trial setting such as the RECORD3 study may not be predictive for your clinical setting.

Procedures per year

Elective hip replacement surgeries performed per year

Number of events

Symptomatic VTE avoided §
Major VTE avoided
Total VTE avoided
Additional bleeding *

§ Symptomatic VTE was similar in both treatment groups

* Bleeding was similar in both treatment groups; major and non-major bleeding combined; see publication for detailed definition 2

RECORD1 trial compared 10 mg rivaroxaban with 40 mg enoxaparin for 5 weeks in 4541 patients undergoing elective hip replacement surgery. Calculations based on RECORD1 data published in the New England Journal of Medicine 2; numbers rounded to full digits.

Note, the experience reported from a controlled clinical trial setting such as the RECORD1 study may not be predictive for your clinical setting.

Find out more about the RECORD programme >
 
  • 4 - Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.
  • 2 - Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.
Venous thromboembolism
A disease process beginning with a blood clot occurring within the venous system, including deep vein thrombosis and pulmonary embolism.